nodes	percent_of_prediction	percent_of_DWPC	metapath
Levorphanol—OPRD1—Peptide GPCRs—ACKR1—acquired immunodeficiency syndrome	0.00687	0.029	CbGpPWpGaD
Levorphanol—OPRM1—nerve—acquired immunodeficiency syndrome	0.00615	0.255	CbGeAlD
Levorphanol—OPRK1—Peptide GPCRs—ACKR1—acquired immunodeficiency syndrome	0.00603	0.0254	CbGpPWpGaD
Levorphanol—OPRD1—Peptide ligand-binding receptors—CCL3L1—acquired immunodeficiency syndrome	0.00534	0.0225	CbGpPWpGaD
Levorphanol—OPRM1—Peptide GPCRs—ACKR1—acquired immunodeficiency syndrome	0.00509	0.0215	CbGpPWpGaD
Levorphanol—OPRK1—Peptide ligand-binding receptors—CCL3L1—acquired immunodeficiency syndrome	0.00468	0.0197	CbGpPWpGaD
Levorphanol—OPRM1—Peptide ligand-binding receptors—CCL3L1—acquired immunodeficiency syndrome	0.00395	0.0167	CbGpPWpGaD
Levorphanol—OPRD1—Peptide GPCRs—CCR2—acquired immunodeficiency syndrome	0.00384	0.0162	CbGpPWpGaD
Levorphanol—OPRD1—Peptide GPCRs—CXCR4—acquired immunodeficiency syndrome	0.00361	0.0152	CbGpPWpGaD
Levorphanol—OPRD1—Class A/1 (Rhodopsin-like receptors)—CCL3L1—acquired immunodeficiency syndrome	0.00358	0.0151	CbGpPWpGaD
Levorphanol—OPRK1—Peptide GPCRs—CCR2—acquired immunodeficiency syndrome	0.00337	0.0142	CbGpPWpGaD
Levorphanol—Lethargy—Saquinavir—acquired immunodeficiency syndrome	0.00327	0.00443	CcSEcCtD
Levorphanol—OPRD1—Peptide ligand-binding receptors—ACKR1—acquired immunodeficiency syndrome	0.00323	0.0136	CbGpPWpGaD
Levorphanol—Dysuria—Indinavir—acquired immunodeficiency syndrome	0.00322	0.00436	CcSEcCtD
Levorphanol—Urinary retention—Ritonavir—acquired immunodeficiency syndrome	0.00317	0.00429	CcSEcCtD
Levorphanol—Sweating—Zidovudine—acquired immunodeficiency syndrome	0.00317	0.00429	CcSEcCtD
Levorphanol—OPRK1—Peptide GPCRs—CXCR4—acquired immunodeficiency syndrome	0.00317	0.0133	CbGpPWpGaD
Levorphanol—Mood swings—Ritonavir—acquired immunodeficiency syndrome	0.00316	0.00427	CcSEcCtD
Levorphanol—OPRK1—Class A/1 (Rhodopsin-like receptors)—CCL3L1—acquired immunodeficiency syndrome	0.00314	0.0132	CbGpPWpGaD
Levorphanol—Renal failure—Indinavir—acquired immunodeficiency syndrome	0.00302	0.00409	CcSEcCtD
Levorphanol—Affect lability—Lamivudine—acquired immunodeficiency syndrome	0.00301	0.00408	CcSEcCtD
Levorphanol—Sweating—Indinavir—acquired immunodeficiency syndrome	0.00294	0.00399	CcSEcCtD
Levorphanol—OPRD1—Peptide ligand-binding receptors—CCL4—acquired immunodeficiency syndrome	0.00292	0.0123	CbGpPWpGaD
Levorphanol—Mood swings—Lamivudine—acquired immunodeficiency syndrome	0.0029	0.00392	CcSEcCtD
Levorphanol—Muscle spasms—Nelfinavir—acquired immunodeficiency syndrome	0.00286	0.00388	CcSEcCtD
Levorphanol—Renal failure—Efavirenz—acquired immunodeficiency syndrome	0.00285	0.00386	CcSEcCtD
Levorphanol—Dry mouth—Didanosine—acquired immunodeficiency syndrome	0.00285	0.00386	CcSEcCtD
Levorphanol—OPRM1—Peptide GPCRs—CCR2—acquired immunodeficiency syndrome	0.00285	0.012	CbGpPWpGaD
Levorphanol—OPRK1—Peptide ligand-binding receptors—ACKR1—acquired immunodeficiency syndrome	0.00283	0.012	CbGpPWpGaD
Levorphanol—Sweating—Efavirenz—acquired immunodeficiency syndrome	0.00278	0.00377	CcSEcCtD
Levorphanol—Agitation—Nelfinavir—acquired immunodeficiency syndrome	0.00274	0.00371	CcSEcCtD
Levorphanol—OPRD1—GPCR ligand binding—CCL3L1—acquired immunodeficiency syndrome	0.00273	0.0115	CbGpPWpGaD
Levorphanol—Dysuria—Ritonavir—acquired immunodeficiency syndrome	0.00269	0.00365	CcSEcCtD
Levorphanol—OPRM1—Peptide GPCRs—CXCR4—acquired immunodeficiency syndrome	0.00268	0.0113	CbGpPWpGaD
Levorphanol—OPRM1—Class A/1 (Rhodopsin-like receptors)—CCL3L1—acquired immunodeficiency syndrome	0.00265	0.0112	CbGpPWpGaD
Levorphanol—Convulsion—Nelfinavir—acquired immunodeficiency syndrome	0.00258	0.00349	CcSEcCtD
Levorphanol—OPRK1—Peptide ligand-binding receptors—CCL4—acquired immunodeficiency syndrome	0.00256	0.0108	CbGpPWpGaD
Levorphanol—Flushing—Indinavir—acquired immunodeficiency syndrome	0.00256	0.00346	CcSEcCtD
Levorphanol—Bradycardia—Delavirdine—acquired immunodeficiency syndrome	0.00254	0.00344	CcSEcCtD
Levorphanol—Convulsion—Abacavir—acquired immunodeficiency syndrome	0.00253	0.00343	CcSEcCtD
Levorphanol—Tension—Zidovudine—acquired immunodeficiency syndrome	0.00253	0.00343	CcSEcCtD
Levorphanol—Renal failure—Ritonavir—acquired immunodeficiency syndrome	0.00252	0.00342	CcSEcCtD
Levorphanol—Visual impairment—Efavirenz—acquired immunodeficiency syndrome	0.00251	0.0034	CcSEcCtD
Levorphanol—Nervousness—Zidovudine—acquired immunodeficiency syndrome	0.00251	0.00339	CcSEcCtD
Levorphanol—Gastrointestinal pain—Amprenavir—acquired immunodeficiency syndrome	0.0025	0.00339	CcSEcCtD
Levorphanol—Muscle spasms—Zidovudine—acquired immunodeficiency syndrome	0.00248	0.00336	CcSEcCtD
Levorphanol—OPRD1—Peptide GPCRs—CCR5—acquired immunodeficiency syndrome	0.00247	0.0104	CbGpPWpGaD
Levorphanol—Dysuria—Lamivudine—acquired immunodeficiency syndrome	0.00247	0.00335	CcSEcCtD
Levorphanol—Dry mouth—Stavudine—acquired immunodeficiency syndrome	0.00247	0.00335	CcSEcCtD
Levorphanol—Sweating—Ritonavir—acquired immunodeficiency syndrome	0.00246	0.00333	CcSEcCtD
Levorphanol—Dyspepsia—Didanosine—acquired immunodeficiency syndrome	0.00246	0.00333	CcSEcCtD
Levorphanol—Renal failure—Saquinavir—acquired immunodeficiency syndrome	0.00243	0.00329	CcSEcCtD
Levorphanol—Abdominal pain—Amprenavir—acquired immunodeficiency syndrome	0.00242	0.00328	CcSEcCtD
Levorphanol—Flushing—Efavirenz—acquired immunodeficiency syndrome	0.00242	0.00327	CcSEcCtD
Levorphanol—OPRM1—Peptide ligand-binding receptors—ACKR1—acquired immunodeficiency syndrome	0.0024	0.0101	CbGpPWpGaD
Levorphanol—OPRK1—GPCR ligand binding—CCL3L1—acquired immunodeficiency syndrome	0.00239	0.0101	CbGpPWpGaD
Levorphanol—Tension—Indinavir—acquired immunodeficiency syndrome	0.00236	0.00319	CcSEcCtD
Levorphanol—Hyperhidrosis—Nelfinavir—acquired immunodeficiency syndrome	0.00235	0.00318	CcSEcCtD
Levorphanol—Hyperhidrosis—Stavudine—acquired immunodeficiency syndrome	0.00234	0.00317	CcSEcCtD
Levorphanol—OPRM1—IL4-mediated signaling events—IL10—acquired immunodeficiency syndrome	0.00234	0.00985	CbGpPWpGaD
Levorphanol—OPRM1—IL4-mediated signaling events—CD40LG—acquired immunodeficiency syndrome	0.00234	0.00985	CbGpPWpGaD
Levorphanol—Nervousness—Indinavir—acquired immunodeficiency syndrome	0.00233	0.00316	CcSEcCtD
Levorphanol—Arrhythmia—Efavirenz—acquired immunodeficiency syndrome	0.00233	0.00315	CcSEcCtD
Levorphanol—Renal failure—Lamivudine—acquired immunodeficiency syndrome	0.00232	0.00314	CcSEcCtD
Levorphanol—Muscle spasms—Indinavir—acquired immunodeficiency syndrome	0.00231	0.00312	CcSEcCtD
Levorphanol—Gastrointestinal pain—Didanosine—acquired immunodeficiency syndrome	0.00228	0.00309	CcSEcCtD
Levorphanol—OPRM1—IL4-mediated signaling events—IL4—acquired immunodeficiency syndrome	0.00227	0.00958	CbGpPWpGaD
Levorphanol—Sweating—Lamivudine—acquired immunodeficiency syndrome	0.00226	0.00306	CcSEcCtD
Levorphanol—Convulsion—Zidovudine—acquired immunodeficiency syndrome	0.00224	0.00303	CcSEcCtD
Levorphanol—Hypotension—Abacavir—acquired immunodeficiency syndrome	0.00223	0.00302	CcSEcCtD
Levorphanol—Tension—Efavirenz—acquired immunodeficiency syndrome	0.00223	0.00301	CcSEcCtD
Levorphanol—Visual impairment—Ritonavir—acquired immunodeficiency syndrome	0.00222	0.00301	CcSEcCtD
Levorphanol—Abdominal pain—Didanosine—acquired immunodeficiency syndrome	0.00221	0.00299	CcSEcCtD
Levorphanol—Agitation—Indinavir—acquired immunodeficiency syndrome	0.00221	0.00299	CcSEcCtD
Levorphanol—Nervousness—Efavirenz—acquired immunodeficiency syndrome	0.0022	0.00298	CcSEcCtD
Levorphanol—Insomnia—Nelfinavir—acquired immunodeficiency syndrome	0.0022	0.00298	CcSEcCtD
Levorphanol—Insomnia—Stavudine—acquired immunodeficiency syndrome	0.00219	0.00297	CcSEcCtD
Levorphanol—OPRK1—Peptide GPCRs—CCR5—acquired immunodeficiency syndrome	0.00217	0.00915	CbGpPWpGaD
Levorphanol—OPRD1—Class A/1 (Rhodopsin-like receptors)—ACKR1—acquired immunodeficiency syndrome	0.00217	0.00914	CbGpPWpGaD
Levorphanol—Pruritus—Amprenavir—acquired immunodeficiency syndrome	0.00217	0.00293	CcSEcCtD
Levorphanol—OPRM1—Peptide ligand-binding receptors—CCL4—acquired immunodeficiency syndrome	0.00217	0.00913	CbGpPWpGaD
Levorphanol—Insomnia—Abacavir—acquired immunodeficiency syndrome	0.00216	0.00292	CcSEcCtD
Levorphanol—Dyspepsia—Nelfinavir—acquired immunodeficiency syndrome	0.00214	0.0029	CcSEcCtD
Levorphanol—Flushing—Ritonavir—acquired immunodeficiency syndrome	0.00214	0.0029	CcSEcCtD
Levorphanol—Visual impairment—Saquinavir—acquired immunodeficiency syndrome	0.00214	0.00289	CcSEcCtD
Levorphanol—Dyspepsia—Stavudine—acquired immunodeficiency syndrome	0.00213	0.00289	CcSEcCtD
Levorphanol—Tension—Delavirdine—acquired immunodeficiency syndrome	0.00213	0.00288	CcSEcCtD
Levorphanol—Confusional state—Zidovudine—acquired immunodeficiency syndrome	0.00212	0.00288	CcSEcCtD
Levorphanol—Palpitations—Indinavir—acquired immunodeficiency syndrome	0.00212	0.00287	CcSEcCtD
Levorphanol—Nervousness—Delavirdine—acquired immunodeficiency syndrome	0.00211	0.00285	CcSEcCtD
Levorphanol—Muscle spasms—Delavirdine—acquired immunodeficiency syndrome	0.00209	0.00282	CcSEcCtD
Levorphanol—Agitation—Efavirenz—acquired immunodeficiency syndrome	0.00208	0.00282	CcSEcCtD
Levorphanol—Constipation—Stavudine—acquired immunodeficiency syndrome	0.00207	0.00281	CcSEcCtD
Levorphanol—Shock—Zidovudine—acquired immunodeficiency syndrome	0.00207	0.00281	CcSEcCtD
Levorphanol—Feeling abnormal—Nevirapine—acquired immunodeficiency syndrome	0.00207	0.0028	CcSEcCtD
Levorphanol—Gastrointestinal pain—Nevirapine—acquired immunodeficiency syndrome	0.00205	0.00278	CcSEcCtD
Levorphanol—Hyperhidrosis—Zidovudine—acquired immunodeficiency syndrome	0.00204	0.00276	CcSEcCtD
Levorphanol—OPRD1—nervous system—acquired immunodeficiency syndrome	0.00203	0.0841	CbGeAlD
Levorphanol—OPRM1—GPCR ligand binding—CCL3L1—acquired immunodeficiency syndrome	0.00202	0.00852	CbGpPWpGaD
Levorphanol—Palpitations—Efavirenz—acquired immunodeficiency syndrome	0.002	0.00271	CcSEcCtD
Levorphanol—Feeling abnormal—Nelfinavir—acquired immunodeficiency syndrome	0.002	0.00271	CcSEcCtD
Levorphanol—Dry mouth—Indinavir—acquired immunodeficiency syndrome	0.002	0.00271	CcSEcCtD
Levorphanol—OPRD1—Peptide ligand-binding receptors—CCL3—acquired immunodeficiency syndrome	0.002	0.00842	CbGpPWpGaD
Levorphanol—Agitation—Delavirdine—acquired immunodeficiency syndrome	0.00199	0.0027	CcSEcCtD
Levorphanol—Urticaria—Nevirapine—acquired immunodeficiency syndrome	0.00199	0.0027	CcSEcCtD
Levorphanol—Gastrointestinal pain—Nelfinavir—acquired immunodeficiency syndrome	0.00199	0.00269	CcSEcCtD
Levorphanol—Abdominal pain—Nevirapine—acquired immunodeficiency syndrome	0.00198	0.00269	CcSEcCtD
Levorphanol—Gastrointestinal pain—Stavudine—acquired immunodeficiency syndrome	0.00198	0.00268	CcSEcCtD
Levorphanol—Pruritus—Didanosine—acquired immunodeficiency syndrome	0.00198	0.00267	CcSEcCtD
Levorphanol—Tension—Ritonavir—acquired immunodeficiency syndrome	0.00197	0.00267	CcSEcCtD
Levorphanol—Feeling abnormal—Abacavir—acquired immunodeficiency syndrome	0.00197	0.00266	CcSEcCtD
Levorphanol—Convulsion—Efavirenz—acquired immunodeficiency syndrome	0.00197	0.00266	CcSEcCtD
Levorphanol—OPRD1—Class A/1 (Rhodopsin-like receptors)—CCL4—acquired immunodeficiency syndrome	0.00196	0.00827	CbGpPWpGaD
Levorphanol—OPRD1—central nervous system—acquired immunodeficiency syndrome	0.00195	0.081	CbGeAlD
Levorphanol—Gastrointestinal pain—Abacavir—acquired immunodeficiency syndrome	0.00195	0.00264	CcSEcCtD
Levorphanol—Nervousness—Ritonavir—acquired immunodeficiency syndrome	0.00195	0.00264	CcSEcCtD
Levorphanol—Vomiting—Amprenavir—acquired immunodeficiency syndrome	0.00195	0.00264	CcSEcCtD
Levorphanol—OPRK1—nervous system—acquired immunodeficiency syndrome	0.00195	0.0807	CbGeAlD
Levorphanol—Urticaria—Nelfinavir—acquired immunodeficiency syndrome	0.00193	0.00261	CcSEcCtD
Levorphanol—Rash—Amprenavir—acquired immunodeficiency syndrome	0.00193	0.00261	CcSEcCtD
Levorphanol—Muscle spasms—Ritonavir—acquired immunodeficiency syndrome	0.00193	0.00261	CcSEcCtD
Levorphanol—Dermatitis—Amprenavir—acquired immunodeficiency syndrome	0.00193	0.00261	CcSEcCtD
Levorphanol—Shock—Indinavir—acquired immunodeficiency syndrome	0.00193	0.00261	CcSEcCtD
Levorphanol—Urticaria—Stavudine—acquired immunodeficiency syndrome	0.00193	0.00261	CcSEcCtD
Levorphanol—Abdominal pain—Nelfinavir—acquired immunodeficiency syndrome	0.00192	0.0026	CcSEcCtD
Levorphanol—Palpitations—Delavirdine—acquired immunodeficiency syndrome	0.00192	0.0026	CcSEcCtD
Levorphanol—Abdominal pain—Stavudine—acquired immunodeficiency syndrome	0.00192	0.00259	CcSEcCtD
Levorphanol—Insomnia—Zidovudine—acquired immunodeficiency syndrome	0.00191	0.00258	CcSEcCtD
Levorphanol—OPRK1—Class A/1 (Rhodopsin-like receptors)—ACKR1—acquired immunodeficiency syndrome	0.0019	0.00802	CbGpPWpGaD
Levorphanol—Urticaria—Abacavir—acquired immunodeficiency syndrome	0.0019	0.00257	CcSEcCtD
Levorphanol—Hyperhidrosis—Indinavir—acquired immunodeficiency syndrome	0.00189	0.00256	CcSEcCtD
Levorphanol—Dry mouth—Efavirenz—acquired immunodeficiency syndrome	0.00189	0.00256	CcSEcCtD
Levorphanol—Abdominal pain—Abacavir—acquired immunodeficiency syndrome	0.00189	0.00256	CcSEcCtD
Levorphanol—OPRK1—central nervous system—acquired immunodeficiency syndrome	0.00187	0.0777	CbGeAlD
Levorphanol—Confusional state—Efavirenz—acquired immunodeficiency syndrome	0.00187	0.00253	CcSEcCtD
Levorphanol—Muscle spasms—Saquinavir—acquired immunodeficiency syndrome	0.00186	0.00251	CcSEcCtD
Levorphanol—Dyspepsia—Zidovudine—acquired immunodeficiency syndrome	0.00185	0.00251	CcSEcCtD
Levorphanol—Agitation—Ritonavir—acquired immunodeficiency syndrome	0.00184	0.0025	CcSEcCtD
Levorphanol—OPRM1—Peptide GPCRs—CCR5—acquired immunodeficiency syndrome	0.00183	0.00773	CbGpPWpGaD
Levorphanol—Shock—Efavirenz—acquired immunodeficiency syndrome	0.00182	0.00247	CcSEcCtD
Levorphanol—Nausea—Amprenavir—acquired immunodeficiency syndrome	0.00182	0.00246	CcSEcCtD
Levorphanol—Tension—Lamivudine—acquired immunodeficiency syndrome	0.00181	0.00245	CcSEcCtD
Levorphanol—Dry mouth—Delavirdine—acquired immunodeficiency syndrome	0.00181	0.00245	CcSEcCtD
Levorphanol—Tachycardia—Efavirenz—acquired immunodeficiency syndrome	0.00181	0.00245	CcSEcCtD
Levorphanol—OPRD1—Peptide ligand-binding receptors—CCR2—acquired immunodeficiency syndrome	0.00181	0.00761	CbGpPWpGaD
Levorphanol—Constipation—Zidovudine—acquired immunodeficiency syndrome	0.0018	0.00244	CcSEcCtD
Levorphanol—Nervousness—Lamivudine—acquired immunodeficiency syndrome	0.00179	0.00242	CcSEcCtD
Levorphanol—Hyperhidrosis—Efavirenz—acquired immunodeficiency syndrome	0.00179	0.00242	CcSEcCtD
Levorphanol—Confusional state—Delavirdine—acquired immunodeficiency syndrome	0.00179	0.00242	CcSEcCtD
Levorphanol—Pruritus—Nevirapine—acquired immunodeficiency syndrome	0.00178	0.0024	CcSEcCtD
Levorphanol—Vomiting—Didanosine—acquired immunodeficiency syndrome	0.00178	0.0024	CcSEcCtD
Levorphanol—Agitation—Saquinavir—acquired immunodeficiency syndrome	0.00178	0.0024	CcSEcCtD
Levorphanol—Palpitations—Ritonavir—acquired immunodeficiency syndrome	0.00177	0.0024	CcSEcCtD
Levorphanol—Insomnia—Indinavir—acquired immunodeficiency syndrome	0.00177	0.0024	CcSEcCtD
Levorphanol—Muscle spasms—Lamivudine—acquired immunodeficiency syndrome	0.00177	0.0024	CcSEcCtD
Levorphanol—Rash—Didanosine—acquired immunodeficiency syndrome	0.00176	0.00238	CcSEcCtD
Levorphanol—Dermatitis—Didanosine—acquired immunodeficiency syndrome	0.00176	0.00238	CcSEcCtD
Levorphanol—OPRK1—Peptide ligand-binding receptors—CCL3—acquired immunodeficiency syndrome	0.00175	0.00738	CbGpPWpGaD
Levorphanol—Shock—Delavirdine—acquired immunodeficiency syndrome	0.00174	0.00236	CcSEcCtD
Levorphanol—Convulsion—Ritonavir—acquired immunodeficiency syndrome	0.00174	0.00235	CcSEcCtD
Levorphanol—Feeling abnormal—Zidovudine—acquired immunodeficiency syndrome	0.00174	0.00235	CcSEcCtD
Levorphanol—Tachycardia—Delavirdine—acquired immunodeficiency syndrome	0.00173	0.00234	CcSEcCtD
Levorphanol—Dyspepsia—Indinavir—acquired immunodeficiency syndrome	0.00172	0.00233	CcSEcCtD
Levorphanol—Gastrointestinal pain—Zidovudine—acquired immunodeficiency syndrome	0.00172	0.00233	CcSEcCtD
Levorphanol—Pruritus—Nelfinavir—acquired immunodeficiency syndrome	0.00172	0.00233	CcSEcCtD
Levorphanol—OPRK1—Class A/1 (Rhodopsin-like receptors)—CCL4—acquired immunodeficiency syndrome	0.00172	0.00725	CbGpPWpGaD
Levorphanol—Pruritus—Stavudine—acquired immunodeficiency syndrome	0.00171	0.00232	CcSEcCtD
Levorphanol—OPRM1—TCR Signaling Pathway—CD8A—acquired immunodeficiency syndrome	0.00171	0.00723	CbGpPWpGaD
Levorphanol—Hyperhidrosis—Delavirdine—acquired immunodeficiency syndrome	0.00171	0.00232	CcSEcCtD
Levorphanol—OPRM1—blood—acquired immunodeficiency syndrome	0.0017	0.0707	CbGeAlD
Levorphanol—OPRD1—Peptide ligand-binding receptors—CXCL12—acquired immunodeficiency syndrome	0.0017	0.00716	CbGpPWpGaD
Levorphanol—OPRD1—Peptide ligand-binding receptors—CXCR4—acquired immunodeficiency syndrome	0.0017	0.00716	CbGpPWpGaD
Levorphanol—Pruritus—Abacavir—acquired immunodeficiency syndrome	0.00169	0.00229	CcSEcCtD
Levorphanol—Constipation—Indinavir—acquired immunodeficiency syndrome	0.00168	0.00227	CcSEcCtD
Levorphanol—Insomnia—Efavirenz—acquired immunodeficiency syndrome	0.00167	0.00227	CcSEcCtD
Levorphanol—Urticaria—Zidovudine—acquired immunodeficiency syndrome	0.00167	0.00227	CcSEcCtD
Levorphanol—Convulsion—Saquinavir—acquired immunodeficiency syndrome	0.00167	0.00227	CcSEcCtD
Levorphanol—Dry mouth—Ritonavir—acquired immunodeficiency syndrome	0.00167	0.00226	CcSEcCtD
Levorphanol—Abdominal pain—Zidovudine—acquired immunodeficiency syndrome	0.00167	0.00225	CcSEcCtD
Levorphanol—Nausea—Didanosine—acquired immunodeficiency syndrome	0.00166	0.00224	CcSEcCtD
Levorphanol—Hypotension—Delavirdine—acquired immunodeficiency syndrome	0.00165	0.00224	CcSEcCtD
Levorphanol—Confusional state—Ritonavir—acquired immunodeficiency syndrome	0.00165	0.00224	CcSEcCtD
Levorphanol—OPRD1—GPCR ligand binding—ACKR1—acquired immunodeficiency syndrome	0.00165	0.00696	CbGpPWpGaD
Levorphanol—OPRM1—spinal cord—acquired immunodeficiency syndrome	0.00164	0.0681	CbGeAlD
Levorphanol—Dyspepsia—Efavirenz—acquired immunodeficiency syndrome	0.00163	0.00221	CcSEcCtD
Levorphanol—Feeling abnormal—Indinavir—acquired immunodeficiency syndrome	0.00161	0.00219	CcSEcCtD
Levorphanol—Shock—Ritonavir—acquired immunodeficiency syndrome	0.00161	0.00218	CcSEcCtD
Levorphanol—Dry mouth—Saquinavir—acquired immunodeficiency syndrome	0.00161	0.00218	CcSEcCtD
Levorphanol—Dizziness—Nelfinavir—acquired immunodeficiency syndrome	0.00161	0.00218	CcSEcCtD
Levorphanol—OPRM1—Class A/1 (Rhodopsin-like receptors)—ACKR1—acquired immunodeficiency syndrome	0.00161	0.00678	CbGpPWpGaD
Levorphanol—Dizziness—Stavudine—acquired immunodeficiency syndrome	0.0016	0.00217	CcSEcCtD
Levorphanol—Gastrointestinal pain—Indinavir—acquired immunodeficiency syndrome	0.0016	0.00217	CcSEcCtD
Levorphanol—Insomnia—Delavirdine—acquired immunodeficiency syndrome	0.0016	0.00217	CcSEcCtD
Levorphanol—Tachycardia—Ritonavir—acquired immunodeficiency syndrome	0.0016	0.00216	CcSEcCtD
Levorphanol—Convulsion—Lamivudine—acquired immunodeficiency syndrome	0.0016	0.00216	CcSEcCtD
Levorphanol—Vomiting—Nevirapine—acquired immunodeficiency syndrome	0.0016	0.00216	CcSEcCtD
Levorphanol—Confusional state—Saquinavir—acquired immunodeficiency syndrome	0.00159	0.00215	CcSEcCtD
Levorphanol—OPRK1—Peptide ligand-binding receptors—CCR2—acquired immunodeficiency syndrome	0.00158	0.00668	CbGpPWpGaD
Levorphanol—Hyperhidrosis—Ritonavir—acquired immunodeficiency syndrome	0.00158	0.00214	CcSEcCtD
Levorphanol—Constipation—Efavirenz—acquired immunodeficiency syndrome	0.00158	0.00214	CcSEcCtD
Levorphanol—Rash—Nevirapine—acquired immunodeficiency syndrome	0.00158	0.00214	CcSEcCtD
Levorphanol—Dermatitis—Nevirapine—acquired immunodeficiency syndrome	0.00158	0.00214	CcSEcCtD
Levorphanol—Dizziness—Abacavir—acquired immunodeficiency syndrome	0.00158	0.00214	CcSEcCtD
Levorphanol—OPRM1—TCR Signaling Pathway—CCR5—acquired immunodeficiency syndrome	0.00157	0.00661	CbGpPWpGaD
Levorphanol—Dyspepsia—Delavirdine—acquired immunodeficiency syndrome	0.00156	0.00211	CcSEcCtD
Levorphanol—Urticaria—Indinavir—acquired immunodeficiency syndrome	0.00156	0.00211	CcSEcCtD
Levorphanol—OPRD1—brain—acquired immunodeficiency syndrome	0.00155	0.0643	CbGeAlD
Levorphanol—Shock—Saquinavir—acquired immunodeficiency syndrome	0.00155	0.0021	CcSEcCtD
Levorphanol—Abdominal pain—Indinavir—acquired immunodeficiency syndrome	0.00155	0.0021	CcSEcCtD
Levorphanol—Vomiting—Nelfinavir—acquired immunodeficiency syndrome	0.00155	0.00209	CcSEcCtD
Levorphanol—Vomiting—Stavudine—acquired immunodeficiency syndrome	0.00154	0.00209	CcSEcCtD
Levorphanol—Dry mouth—Lamivudine—acquired immunodeficiency syndrome	0.00153	0.00208	CcSEcCtD
Levorphanol—Rash—Nelfinavir—acquired immunodeficiency syndrome	0.00153	0.00208	CcSEcCtD
Levorphanol—Dermatitis—Nelfinavir—acquired immunodeficiency syndrome	0.00153	0.00207	CcSEcCtD
Levorphanol—Hypotension—Ritonavir—acquired immunodeficiency syndrome	0.00153	0.00207	CcSEcCtD
Levorphanol—Rash—Stavudine—acquired immunodeficiency syndrome	0.00153	0.00207	CcSEcCtD
Levorphanol—Dermatitis—Stavudine—acquired immunodeficiency syndrome	0.00153	0.00207	CcSEcCtD
Levorphanol—Feeling abnormal—Efavirenz—acquired immunodeficiency syndrome	0.00153	0.00206	CcSEcCtD
Levorphanol—Hyperhidrosis—Saquinavir—acquired immunodeficiency syndrome	0.00152	0.00206	CcSEcCtD
Levorphanol—OPRD1—G alpha (i) signalling events—CCR2—acquired immunodeficiency syndrome	0.00152	0.00642	CbGpPWpGaD
Levorphanol—Vomiting—Abacavir—acquired immunodeficiency syndrome	0.00152	0.00206	CcSEcCtD
Levorphanol—Confusional state—Lamivudine—acquired immunodeficiency syndrome	0.00152	0.00205	CcSEcCtD
Levorphanol—Constipation—Delavirdine—acquired immunodeficiency syndrome	0.00151	0.00205	CcSEcCtD
Levorphanol—Gastrointestinal pain—Efavirenz—acquired immunodeficiency syndrome	0.00151	0.00205	CcSEcCtD
Levorphanol—Rash—Abacavir—acquired immunodeficiency syndrome	0.00151	0.00204	CcSEcCtD
Levorphanol—Dermatitis—Abacavir—acquired immunodeficiency syndrome	0.0015	0.00204	CcSEcCtD
Levorphanol—OPRD1—GPCR ligand binding—CCL4—acquired immunodeficiency syndrome	0.00149	0.0063	CbGpPWpGaD
Levorphanol—Nausea—Nevirapine—acquired immunodeficiency syndrome	0.00149	0.00202	CcSEcCtD
Levorphanol—Pruritus—Zidovudine—acquired immunodeficiency syndrome	0.00149	0.00202	CcSEcCtD
Levorphanol—OPRK1—Peptide ligand-binding receptors—CXCR4—acquired immunodeficiency syndrome	0.00149	0.00628	CbGpPWpGaD
Levorphanol—OPRK1—Peptide ligand-binding receptors—CXCL12—acquired immunodeficiency syndrome	0.00149	0.00628	CbGpPWpGaD
Levorphanol—OPRK1—brain—acquired immunodeficiency syndrome	0.00149	0.0617	CbGeAlD
Levorphanol—Insomnia—Ritonavir—acquired immunodeficiency syndrome	0.00148	0.00201	CcSEcCtD
Levorphanol—OPRM1—Peptide ligand-binding receptors—CCL3—acquired immunodeficiency syndrome	0.00148	0.00624	CbGpPWpGaD
Levorphanol—Shock—Lamivudine—acquired immunodeficiency syndrome	0.00148	0.002	CcSEcCtD
Levorphanol—Hypotension—Saquinavir—acquired immunodeficiency syndrome	0.00147	0.00199	CcSEcCtD
Levorphanol—Urticaria—Efavirenz—acquired immunodeficiency syndrome	0.00147	0.00199	CcSEcCtD
Levorphanol—Abdominal pain—Efavirenz—acquired immunodeficiency syndrome	0.00146	0.00198	CcSEcCtD
Levorphanol—Feeling abnormal—Delavirdine—acquired immunodeficiency syndrome	0.00146	0.00198	CcSEcCtD
Levorphanol—Hyperhidrosis—Lamivudine—acquired immunodeficiency syndrome	0.00145	0.00197	CcSEcCtD
Levorphanol—OPRM1—Class A/1 (Rhodopsin-like receptors)—CCL4—acquired immunodeficiency syndrome	0.00145	0.00613	CbGpPWpGaD
Levorphanol—Gastrointestinal pain—Delavirdine—acquired immunodeficiency syndrome	0.00145	0.00196	CcSEcCtD
Levorphanol—OPRK1—GPCR ligand binding—ACKR1—acquired immunodeficiency syndrome	0.00145	0.0061	CbGpPWpGaD
Levorphanol—Nausea—Nelfinavir—acquired immunodeficiency syndrome	0.00144	0.00195	CcSEcCtD
Levorphanol—Dyspepsia—Ritonavir—acquired immunodeficiency syndrome	0.00144	0.00195	CcSEcCtD
Levorphanol—Nausea—Stavudine—acquired immunodeficiency syndrome	0.00144	0.00195	CcSEcCtD
Levorphanol—OPRD1—G alpha (i) signalling events—CXCR4—acquired immunodeficiency syndrome	0.00143	0.00604	CbGpPWpGaD
Levorphanol—OPRD1—G alpha (i) signalling events—CXCL12—acquired immunodeficiency syndrome	0.00143	0.00604	CbGpPWpGaD
Levorphanol—Insomnia—Saquinavir—acquired immunodeficiency syndrome	0.00143	0.00193	CcSEcCtD
Levorphanol—Nausea—Abacavir—acquired immunodeficiency syndrome	0.00142	0.00192	CcSEcCtD
Levorphanol—OPRD1—GPCRs, Class A Rhodopsin-like—CCR2—acquired immunodeficiency syndrome	0.00141	0.00596	CbGpPWpGaD
Levorphanol—Urticaria—Delavirdine—acquired immunodeficiency syndrome	0.00141	0.0019	CcSEcCtD
Levorphanol—Hypotension—Lamivudine—acquired immunodeficiency syndrome	0.00141	0.0019	CcSEcCtD
Levorphanol—Constipation—Ritonavir—acquired immunodeficiency syndrome	0.0014	0.0019	CcSEcCtD
Levorphanol—Abdominal pain—Delavirdine—acquired immunodeficiency syndrome	0.0014	0.0019	CcSEcCtD
Levorphanol—OPRD1—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	0.0014	0.0059	CbGpPWpGaD
Levorphanol—Dizziness—Zidovudine—acquired immunodeficiency syndrome	0.00139	0.00189	CcSEcCtD
Levorphanol—Dyspepsia—Saquinavir—acquired immunodeficiency syndrome	0.00139	0.00188	CcSEcCtD
Levorphanol—Pruritus—Indinavir—acquired immunodeficiency syndrome	0.00139	0.00188	CcSEcCtD
Levorphanol—OPRM1—nervous system—acquired immunodeficiency syndrome	0.00138	0.0574	CbGeAlD
Levorphanol—Insomnia—Lamivudine—acquired immunodeficiency syndrome	0.00136	0.00184	CcSEcCtD
Levorphanol—Feeling abnormal—Ritonavir—acquired immunodeficiency syndrome	0.00135	0.00183	CcSEcCtD
Levorphanol—Constipation—Saquinavir—acquired immunodeficiency syndrome	0.00135	0.00182	CcSEcCtD
Levorphanol—OPRD1—Class A/1 (Rhodopsin-like receptors)—CCL3—acquired immunodeficiency syndrome	0.00134	0.00565	CbGpPWpGaD
Levorphanol—Vomiting—Zidovudine—acquired immunodeficiency syndrome	0.00134	0.00181	CcSEcCtD
Levorphanol—Gastrointestinal pain—Ritonavir—acquired immunodeficiency syndrome	0.00134	0.00181	CcSEcCtD
Levorphanol—OPRM1—Peptide ligand-binding receptors—CCR2—acquired immunodeficiency syndrome	0.00134	0.00564	CbGpPWpGaD
Levorphanol—OPRK1—G alpha (i) signalling events—CCR2—acquired immunodeficiency syndrome	0.00134	0.00563	CbGpPWpGaD
Levorphanol—OPRM1—central nervous system—acquired immunodeficiency syndrome	0.00133	0.0553	CbGeAlD
Levorphanol—OPRD1—GPCRs, Class A Rhodopsin-like—CXCR4—acquired immunodeficiency syndrome	0.00133	0.00561	CbGpPWpGaD
Levorphanol—Rash—Zidovudine—acquired immunodeficiency syndrome	0.00133	0.0018	CcSEcCtD
Levorphanol—Dermatitis—Zidovudine—acquired immunodeficiency syndrome	0.00133	0.0018	CcSEcCtD
Levorphanol—Dyspepsia—Lamivudine—acquired immunodeficiency syndrome	0.00132	0.00179	CcSEcCtD
Levorphanol—Pruritus—Efavirenz—acquired immunodeficiency syndrome	0.00131	0.00177	CcSEcCtD
Levorphanol—OPRK1—GPCR ligand binding—CCL4—acquired immunodeficiency syndrome	0.00131	0.00552	CbGpPWpGaD
Levorphanol—Urticaria—Ritonavir—acquired immunodeficiency syndrome	0.0013	0.00176	CcSEcCtD
Levorphanol—Feeling abnormal—Saquinavir—acquired immunodeficiency syndrome	0.0013	0.00176	CcSEcCtD
Levorphanol—Dizziness—Indinavir—acquired immunodeficiency syndrome	0.0013	0.00175	CcSEcCtD
Levorphanol—Abdominal pain—Ritonavir—acquired immunodeficiency syndrome	0.00129	0.00175	CcSEcCtD
Levorphanol—OPRD1—Peptide ligand-binding receptors—CCL5—acquired immunodeficiency syndrome	0.00129	0.00545	CbGpPWpGaD
Levorphanol—Gastrointestinal pain—Saquinavir—acquired immunodeficiency syndrome	0.00129	0.00174	CcSEcCtD
Levorphanol—Constipation—Lamivudine—acquired immunodeficiency syndrome	0.00129	0.00174	CcSEcCtD
Levorphanol—OPRM1—Peptide ligand-binding receptors—CXCL12—acquired immunodeficiency syndrome	0.00126	0.00531	CbGpPWpGaD
Levorphanol—OPRM1—Peptide ligand-binding receptors—CXCR4—acquired immunodeficiency syndrome	0.00126	0.00531	CbGpPWpGaD
Levorphanol—OPRK1—G alpha (i) signalling events—CXCR4—acquired immunodeficiency syndrome	0.00126	0.0053	CbGpPWpGaD
Levorphanol—OPRK1—G alpha (i) signalling events—CXCL12—acquired immunodeficiency syndrome	0.00126	0.0053	CbGpPWpGaD
Levorphanol—Pruritus—Delavirdine—acquired immunodeficiency syndrome	0.00125	0.0017	CcSEcCtD
Levorphanol—Urticaria—Saquinavir—acquired immunodeficiency syndrome	0.00125	0.0017	CcSEcCtD
Levorphanol—Nausea—Zidovudine—acquired immunodeficiency syndrome	0.00125	0.00169	CcSEcCtD
Levorphanol—Abdominal pain—Saquinavir—acquired immunodeficiency syndrome	0.00125	0.00169	CcSEcCtD
Levorphanol—Vomiting—Indinavir—acquired immunodeficiency syndrome	0.00125	0.00169	CcSEcCtD
Levorphanol—OPRK1—GPCRs, Class A Rhodopsin-like—CCR2—acquired immunodeficiency syndrome	0.00124	0.00523	CbGpPWpGaD
Levorphanol—Feeling abnormal—Lamivudine—acquired immunodeficiency syndrome	0.00124	0.00168	CcSEcCtD
Levorphanol—Rash—Indinavir—acquired immunodeficiency syndrome	0.00124	0.00167	CcSEcCtD
Levorphanol—Dermatitis—Indinavir—acquired immunodeficiency syndrome	0.00123	0.00167	CcSEcCtD
Levorphanol—Gastrointestinal pain—Lamivudine—acquired immunodeficiency syndrome	0.00123	0.00166	CcSEcCtD
Levorphanol—OPRK1—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	0.00123	0.00517	CbGpPWpGaD
Levorphanol—Dizziness—Efavirenz—acquired immunodeficiency syndrome	0.00122	0.00166	CcSEcCtD
Levorphanol—OPRM1—GPCR ligand binding—ACKR1—acquired immunodeficiency syndrome	0.00122	0.00516	CbGpPWpGaD
Levorphanol—OPRD1—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	0.00121	0.00511	CbGpPWpGaD
Levorphanol—Urticaria—Lamivudine—acquired immunodeficiency syndrome	0.00119	0.00162	CcSEcCtD
Levorphanol—Abdominal pain—Lamivudine—acquired immunodeficiency syndrome	0.00119	0.00161	CcSEcCtD
Levorphanol—Vomiting—Efavirenz—acquired immunodeficiency syndrome	0.00118	0.00159	CcSEcCtD
Levorphanol—OPRK1—Class A/1 (Rhodopsin-like receptors)—CCL3—acquired immunodeficiency syndrome	0.00117	0.00495	CbGpPWpGaD
Levorphanol—Dizziness—Delavirdine—acquired immunodeficiency syndrome	0.00117	0.00159	CcSEcCtD
Levorphanol—Rash—Efavirenz—acquired immunodeficiency syndrome	0.00117	0.00158	CcSEcCtD
Levorphanol—Dermatitis—Efavirenz—acquired immunodeficiency syndrome	0.00117	0.00158	CcSEcCtD
Levorphanol—OPRK1—GPCRs, Class A Rhodopsin-like—CXCR4—acquired immunodeficiency syndrome	0.00117	0.00492	CbGpPWpGaD
Levorphanol—OPRD1—Peptide ligand-binding receptors—CCR5—acquired immunodeficiency syndrome	0.00116	0.00491	CbGpPWpGaD
Levorphanol—Nausea—Indinavir—acquired immunodeficiency syndrome	0.00116	0.00158	CcSEcCtD
Levorphanol—Pruritus—Ritonavir—acquired immunodeficiency syndrome	0.00116	0.00157	CcSEcCtD
Levorphanol—OPRD1—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	0.00114	0.0048	CbGpPWpGaD
Levorphanol—OPRD1—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	0.00114	0.0048	CbGpPWpGaD
Levorphanol—OPRK1—Peptide ligand-binding receptors—CCL5—acquired immunodeficiency syndrome	0.00113	0.00478	CbGpPWpGaD
Levorphanol—OPRM1—G alpha (i) signalling events—CCR2—acquired immunodeficiency syndrome	0.00113	0.00476	CbGpPWpGaD
Levorphanol—Vomiting—Delavirdine—acquired immunodeficiency syndrome	0.00113	0.00152	CcSEcCtD
Levorphanol—Rash—Delavirdine—acquired immunodeficiency syndrome	0.00112	0.00151	CcSEcCtD
Levorphanol—Dermatitis—Delavirdine—acquired immunodeficiency syndrome	0.00112	0.00151	CcSEcCtD
Levorphanol—Pruritus—Saquinavir—acquired immunodeficiency syndrome	0.00112	0.00151	CcSEcCtD
Levorphanol—OPRM1—GPCR ligand binding—CCL4—acquired immunodeficiency syndrome	0.00111	0.00467	CbGpPWpGaD
Levorphanol—Nausea—Efavirenz—acquired immunodeficiency syndrome	0.0011	0.00149	CcSEcCtD
Levorphanol—OPRD1—G alpha (i) signalling events—CCL5—acquired immunodeficiency syndrome	0.00109	0.0046	CbGpPWpGaD
Levorphanol—Dizziness—Ritonavir—acquired immunodeficiency syndrome	0.00108	0.00147	CcSEcCtD
Levorphanol—Pruritus—Lamivudine—acquired immunodeficiency syndrome	0.00106	0.00144	CcSEcCtD
Levorphanol—OPRK1—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	0.00106	0.00448	CbGpPWpGaD
Levorphanol—OPRM1—G alpha (i) signalling events—CXCL12—acquired immunodeficiency syndrome	0.00106	0.00448	CbGpPWpGaD
Levorphanol—OPRM1—G alpha (i) signalling events—CXCR4—acquired immunodeficiency syndrome	0.00106	0.00448	CbGpPWpGaD
Levorphanol—OPRM1—brain—acquired immunodeficiency syndrome	0.00106	0.0439	CbGeAlD
Levorphanol—Nausea—Delavirdine—acquired immunodeficiency syndrome	0.00105	0.00142	CcSEcCtD
Levorphanol—OPRM1—GPCRs, Class A Rhodopsin-like—CCR2—acquired immunodeficiency syndrome	0.00105	0.00442	CbGpPWpGaD
Levorphanol—Dizziness—Saquinavir—acquired immunodeficiency syndrome	0.00104	0.00141	CcSEcCtD
Levorphanol—Vomiting—Ritonavir—acquired immunodeficiency syndrome	0.00104	0.00141	CcSEcCtD
Levorphanol—OPRM1—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	0.00104	0.00437	CbGpPWpGaD
Levorphanol—Rash—Ritonavir—acquired immunodeficiency syndrome	0.00103	0.0014	CcSEcCtD
Levorphanol—Dermatitis—Ritonavir—acquired immunodeficiency syndrome	0.00103	0.0014	CcSEcCtD
Levorphanol—OPRK1—Peptide ligand-binding receptors—CCR5—acquired immunodeficiency syndrome	0.00102	0.0043	CbGpPWpGaD
Levorphanol—OPRD1—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	0.00102	0.0043	CbGpPWpGaD
Levorphanol—Vomiting—Saquinavir—acquired immunodeficiency syndrome	0.001	0.00136	CcSEcCtD
Levorphanol—OPRK1—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	0.000999	0.00421	CbGpPWpGaD
Levorphanol—OPRK1—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	0.000999	0.00421	CbGpPWpGaD
Levorphanol—Dizziness—Lamivudine—acquired immunodeficiency syndrome	0.000994	0.00135	CcSEcCtD
Levorphanol—Rash—Saquinavir—acquired immunodeficiency syndrome	0.000994	0.00135	CcSEcCtD
Levorphanol—Dermatitis—Saquinavir—acquired immunodeficiency syndrome	0.000993	0.00134	CcSEcCtD
Levorphanol—OPRM1—Class A/1 (Rhodopsin-like receptors)—CCL3—acquired immunodeficiency syndrome	0.000993	0.00419	CbGpPWpGaD
Levorphanol—OPRM1—GPCRs, Class A Rhodopsin-like—CXCR4—acquired immunodeficiency syndrome	0.000985	0.00415	CbGpPWpGaD
Levorphanol—OPRM1—TCR Signaling Pathway—CD4—acquired immunodeficiency syndrome	0.000985	0.00415	CbGpPWpGaD
Levorphanol—OPRD1—G alpha (i) signalling events—CCR5—acquired immunodeficiency syndrome	0.000982	0.00414	CbGpPWpGaD
Levorphanol—Nausea—Ritonavir—acquired immunodeficiency syndrome	0.000973	0.00132	CcSEcCtD
Levorphanol—OPRM1—Peptide ligand-binding receptors—CCL5—acquired immunodeficiency syndrome	0.000957	0.00404	CbGpPWpGaD
Levorphanol—Vomiting—Lamivudine—acquired immunodeficiency syndrome	0.000956	0.00129	CcSEcCtD
Levorphanol—OPRK1—G alpha (i) signalling events—CCL5—acquired immunodeficiency syndrome	0.000956	0.00403	CbGpPWpGaD
Levorphanol—Rash—Lamivudine—acquired immunodeficiency syndrome	0.000948	0.00128	CcSEcCtD
Levorphanol—Dermatitis—Lamivudine—acquired immunodeficiency syndrome	0.000947	0.00128	CcSEcCtD
Levorphanol—Nausea—Saquinavir—acquired immunodeficiency syndrome	0.000936	0.00127	CcSEcCtD
Levorphanol—OPRD1—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	0.000922	0.00389	CbGpPWpGaD
Levorphanol—OPRD1—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	0.000911	0.00384	CbGpPWpGaD
Levorphanol—OPRM1—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	0.000898	0.00379	CbGpPWpGaD
Levorphanol—OPRK1—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	0.000894	0.00377	CbGpPWpGaD
Levorphanol—Nausea—Lamivudine—acquired immunodeficiency syndrome	0.000893	0.00121	CcSEcCtD
Levorphanol—OPRD1—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	0.000867	0.00366	CbGpPWpGaD
Levorphanol—OPRD1—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	0.000867	0.00366	CbGpPWpGaD
Levorphanol—OPRD1—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	0.000866	0.00365	CbGpPWpGaD
Levorphanol—OPRM1—Peptide ligand-binding receptors—CCR5—acquired immunodeficiency syndrome	0.000862	0.00364	CbGpPWpGaD
Levorphanol—OPRK1—G alpha (i) signalling events—CCR5—acquired immunodeficiency syndrome	0.000861	0.00363	CbGpPWpGaD
Levorphanol—OPRD1—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	0.000847	0.00357	CbGpPWpGaD
Levorphanol—OPRM1—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	0.000844	0.00356	CbGpPWpGaD
Levorphanol—OPRM1—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	0.000844	0.00356	CbGpPWpGaD
Levorphanol—OPRD1—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	0.000826	0.00348	CbGpPWpGaD
Levorphanol—OPRK1—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	0.000809	0.00341	CbGpPWpGaD
Levorphanol—OPRM1—G alpha (i) signalling events—CCL5—acquired immunodeficiency syndrome	0.000808	0.00341	CbGpPWpGaD
Levorphanol—OPRK1—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	0.000799	0.00337	CbGpPWpGaD
Levorphanol—OPRD1—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	0.000781	0.00329	CbGpPWpGaD
Levorphanol—OPRD1—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	0.000766	0.00323	CbGpPWpGaD
Levorphanol—OPRK1—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	0.000761	0.00321	CbGpPWpGaD
Levorphanol—OPRK1—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	0.000761	0.00321	CbGpPWpGaD
Levorphanol—OPRK1—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	0.00076	0.0032	CbGpPWpGaD
Levorphanol—OPRM1—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	0.000756	0.00319	CbGpPWpGaD
Levorphanol—OPRK1—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	0.000743	0.00313	CbGpPWpGaD
Levorphanol—OPRM1—G alpha (i) signalling events—CCR5—acquired immunodeficiency syndrome	0.000728	0.00307	CbGpPWpGaD
Levorphanol—OPRK1—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	0.000724	0.00305	CbGpPWpGaD
Levorphanol—OPRK1—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	0.000685	0.00289	CbGpPWpGaD
Levorphanol—OPRM1—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	0.000684	0.00288	CbGpPWpGaD
Levorphanol—OPRM1—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	0.000675	0.00285	CbGpPWpGaD
Levorphanol—OPRK1—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	0.000672	0.00283	CbGpPWpGaD
Levorphanol—OPRD1—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	0.00066	0.00278	CbGpPWpGaD
Levorphanol—OPRM1—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	0.000643	0.00271	CbGpPWpGaD
Levorphanol—OPRM1—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	0.000643	0.00271	CbGpPWpGaD
Levorphanol—OPRM1—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	0.000642	0.00271	CbGpPWpGaD
Levorphanol—OPRM1—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	0.000628	0.00265	CbGpPWpGaD
Levorphanol—OPRM1—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	0.000612	0.00258	CbGpPWpGaD
Levorphanol—OPRD1—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	0.000594	0.00251	CbGpPWpGaD
Levorphanol—OPRK1—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	0.000579	0.00244	CbGpPWpGaD
Levorphanol—OPRM1—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	0.000579	0.00244	CbGpPWpGaD
Levorphanol—OPRM1—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	0.000568	0.00239	CbGpPWpGaD
Levorphanol—OPRM1—TCR Signaling Pathway—IL6—acquired immunodeficiency syndrome	0.000533	0.00225	CbGpPWpGaD
Levorphanol—OPRD1—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	0.000523	0.00221	CbGpPWpGaD
Levorphanol—OPRD1—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	0.000521	0.0022	CbGpPWpGaD
Levorphanol—OPRK1—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	0.000521	0.0022	CbGpPWpGaD
Levorphanol—OPRD1—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	0.000501	0.00211	CbGpPWpGaD
Levorphanol—OPRD1—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	0.000501	0.00211	CbGpPWpGaD
Levorphanol—OPRD1—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	0.00049	0.00207	CbGpPWpGaD
Levorphanol—OPRD1—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	0.00049	0.00207	CbGpPWpGaD
Levorphanol—OPRM1—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	0.000489	0.00206	CbGpPWpGaD
Levorphanol—OPRD1—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	0.000473	0.002	CbGpPWpGaD
Levorphanol—OPRK1—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	0.000459	0.00194	CbGpPWpGaD
Levorphanol—OPRK1—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	0.000457	0.00193	CbGpPWpGaD
Levorphanol—OPRD1—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	0.000453	0.00191	CbGpPWpGaD
Levorphanol—OPRD1—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	0.000445	0.00188	CbGpPWpGaD
Levorphanol—OPRD1—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	0.000445	0.00188	CbGpPWpGaD
Levorphanol—OPRM1—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	0.000441	0.00186	CbGpPWpGaD
Levorphanol—OPRK1—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	0.000439	0.00185	CbGpPWpGaD
Levorphanol—OPRK1—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	0.000439	0.00185	CbGpPWpGaD
Levorphanol—OPRK1—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	0.00043	0.00181	CbGpPWpGaD
Levorphanol—OPRK1—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	0.00043	0.00181	CbGpPWpGaD
Levorphanol—OPRK1—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	0.000415	0.00175	CbGpPWpGaD
Levorphanol—OPRK1—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	0.000397	0.00167	CbGpPWpGaD
Levorphanol—OPRK1—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	0.00039	0.00165	CbGpPWpGaD
Levorphanol—OPRK1—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	0.00039	0.00165	CbGpPWpGaD
Levorphanol—OPRM1—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	0.000388	0.00164	CbGpPWpGaD
Levorphanol—OPRM1—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	0.000386	0.00163	CbGpPWpGaD
Levorphanol—OPRD1—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	0.000373	0.00157	CbGpPWpGaD
Levorphanol—OPRM1—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	0.000371	0.00156	CbGpPWpGaD
Levorphanol—OPRM1—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	0.000371	0.00156	CbGpPWpGaD
Levorphanol—OPRD1—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	0.000367	0.00155	CbGpPWpGaD
Levorphanol—OPRM1—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	0.000363	0.00153	CbGpPWpGaD
Levorphanol—OPRM1—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	0.000363	0.00153	CbGpPWpGaD
Levorphanol—OPRM1—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	0.000351	0.00148	CbGpPWpGaD
Levorphanol—OPRD1—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	0.000339	0.00143	CbGpPWpGaD
Levorphanol—OPRD1—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	0.000336	0.00142	CbGpPWpGaD
Levorphanol—OPRM1—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	0.000335	0.00141	CbGpPWpGaD
Levorphanol—OPRD1—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	0.000334	0.00141	CbGpPWpGaD
Levorphanol—OPRM1—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	0.00033	0.00139	CbGpPWpGaD
Levorphanol—OPRM1—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	0.00033	0.00139	CbGpPWpGaD
Levorphanol—OPRK1—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	0.000327	0.00138	CbGpPWpGaD
Levorphanol—OPRK1—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	0.000322	0.00136	CbGpPWpGaD
Levorphanol—OPRD1—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	0.000309	0.0013	CbGpPWpGaD
Levorphanol—OPRD1—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	0.000305	0.00129	CbGpPWpGaD
Levorphanol—OPRK1—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	0.000297	0.00125	CbGpPWpGaD
Levorphanol—OPRK1—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	0.000295	0.00124	CbGpPWpGaD
Levorphanol—OPRK1—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	0.000292	0.00123	CbGpPWpGaD
Levorphanol—OPRD1—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	0.00028	0.00118	CbGpPWpGaD
Levorphanol—OPRM1—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	0.000276	0.00117	CbGpPWpGaD
Levorphanol—OPRM1—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	0.000272	0.00115	CbGpPWpGaD
Levorphanol—OPRK1—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	0.000271	0.00114	CbGpPWpGaD
Levorphanol—OPRK1—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	0.000267	0.00113	CbGpPWpGaD
Levorphanol—OPRD1—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	0.000263	0.00111	CbGpPWpGaD
Levorphanol—OPRD1—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	0.000263	0.00111	CbGpPWpGaD
Levorphanol—OPRM1—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	0.000251	0.00106	CbGpPWpGaD
Levorphanol—OPRM1—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	0.000249	0.00105	CbGpPWpGaD
Levorphanol—OPRM1—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	0.000247	0.00104	CbGpPWpGaD
Levorphanol—OPRK1—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	0.000245	0.00103	CbGpPWpGaD
Levorphanol—OPRK1—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	0.000231	0.000972	CbGpPWpGaD
Levorphanol—OPRK1—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	0.000231	0.000972	CbGpPWpGaD
Levorphanol—OPRM1—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	0.000229	0.000966	CbGpPWpGaD
Levorphanol—OPRM1—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	0.000226	0.000953	CbGpPWpGaD
Levorphanol—OPRM1—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	0.000207	0.000874	CbGpPWpGaD
Levorphanol—OPRD1—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	0.0002	0.000843	CbGpPWpGaD
Levorphanol—OPRD1—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	0.000197	0.000831	CbGpPWpGaD
Levorphanol—OPRM1—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	0.000195	0.000822	CbGpPWpGaD
Levorphanol—OPRM1—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	0.000195	0.000822	CbGpPWpGaD
Levorphanol—OPRD1—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	0.000194	0.000818	CbGpPWpGaD
Levorphanol—OPRD1—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	0.00018	0.00076	CbGpPWpGaD
Levorphanol—OPRD1—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	0.000176	0.000743	CbGpPWpGaD
Levorphanol—OPRK1—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	0.000175	0.00074	CbGpPWpGaD
Levorphanol—OPRK1—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	0.000173	0.000728	CbGpPWpGaD
Levorphanol—OPRK1—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	0.00017	0.000718	CbGpPWpGaD
Levorphanol—OPRK1—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	0.000158	0.000666	CbGpPWpGaD
Levorphanol—OPRK1—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	0.000155	0.000652	CbGpPWpGaD
Levorphanol—OPRM1—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	0.000148	0.000625	CbGpPWpGaD
Levorphanol—OPRM1—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	0.000146	0.000616	CbGpPWpGaD
Levorphanol—OPRM1—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	0.000144	0.000607	CbGpPWpGaD
Levorphanol—OPRM1—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	0.000134	0.000563	CbGpPWpGaD
Levorphanol—OPRM1—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	0.000131	0.000551	CbGpPWpGaD
Levorphanol—OPRD1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	0.000104	0.000439	CbGpPWpGaD
Levorphanol—OPRD1—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	0.000104	0.000437	CbGpPWpGaD
Levorphanol—OPRK1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	9.13e-05	0.000385	CbGpPWpGaD
Levorphanol—OPRK1—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	9.08e-05	0.000383	CbGpPWpGaD
Levorphanol—OPRM1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	7.72e-05	0.000325	CbGpPWpGaD
Levorphanol—OPRM1—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	7.68e-05	0.000324	CbGpPWpGaD
Levorphanol—OPRD1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	6.12e-05	0.000258	CbGpPWpGaD
Levorphanol—OPRK1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	5.37e-05	0.000226	CbGpPWpGaD
Levorphanol—OPRM1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	4.54e-05	0.000191	CbGpPWpGaD
